- Met the VCN discontinuation criterion on Study ALD-102, as follows: the subject has undetectable VCN (<0.0003 copies per cell) in peripheral blood cells for 2 consecutive measurements at least 1 month apart and at least 12 months after drug product infusion. This exclusion criterion does not apply to subjects who received allo-HSCT after Lenti-D Drug Product infusion in Study ALD-102.